Crenezumab
Jump to navigation
Jump to search
Mechanism of action
- blocks formation of amyloid-beta oligomers amyloid plaques[3]
Clinical trials
- to be used in a 5 year clinical trial on ~300 family members that carry an autosomal dominant allele of presenilin-1
- Crenezumab did not reduce clinical decline in a phase 3 clinical trial of participants with early Alzheimer's disease[4]
Notes
- Crenezumab was developed by the Swiss-based biopharmaceutical company AC Immune SA, which licensed the drug in 2006 to Genentech[2]
More general terms
Additional terms
References
- ↑ Belluck P New Drug Trial Seeks to Stop Alzheimer's Before It Starts New York Times< May 15, 2012 http://www.nytimes.com/2012/05/16/health/research/prevention-is-goal-of-alzheimers-drug-trial.html
- ↑ 2.0 2.1 Wikipedia: Crenezumab http://en.wikipedia.org/wiki/Crenezumab
- ↑ 3.0 3.1 Yang T, Dang Y, Ostaszewski B, Mengel D et al Target engagement in an alzheimer trial: Crenezumab lowers amyloid beta oligomers in cerebrospinal fluid Ann Neurol. 2019 Aug;86(2):215-224 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31168802 Free PMC article Clinical Trial.
- ↑ 4.0 4.1 Ostrowitzki S, Bittner T, Sink KM et al Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer DiseaseTwo Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurol. 2022;79(11):1113-1121. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36121669 PMCID: PMC9486635 Free PMC article https://jamanetwork.com/journals/jamaneurology/fullarticle/2796551